SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-1.1
Date Filed: 2025-08-27
Accession Number: 0001213900-25-081175
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025081175/ea025480001ex1-1_synergy.htm

Chunk 9 of 27
Word Count: 1421
Character Count: 8694

Document Content:

in accordance with their terms, shall terminate as to twenty-five percent (25%) of the Representative Warrant on the date that is three (3) years after the Closing Date, as to an additional twenty-five percent (25%) of the Representative Warrant Shares on the date that is four (4) years after the Closing Date, and as to the remaining fifty percent (50%) of the Representative Warrant Shares on the date that is five (5) years after the Closing Date. The initial exercise price of the Representative Warrant shall be $2.75 per Share, which is equal to one hundred and ten percent (110%) of the public offering price per Share issued at the Closing. The Representative Warrants shall substantially in the form of Exhibit A hereto, and registered in the name or names and shall be in such denominations as Representative may request at least one (1) business day before the Closing Date.

(e) On the basis of the representations
and warranties herein contained, but subject to the terms and conditions herein set forth, the Company hereby grants to the Underwriters
an option (the “Over-allotment Option”) exercisable for 45 days from the date of this Agreement (the “45-day
period”) to purchase up to 262,500 Additional Shares, representing fifteen percent (15%) of the total number of Shares to be
offered by the Company, solely for the purpose of covering over-allotments in connection with the distribution and sale of the Shares.

(f) The Over-allotment
Option granted pursuant to Section 4(e) hereof may be exercised by the Underwriters on or within the 45-day period. The purchase
price to be paid per Additional Share shall be equal to the purchase price per Share set forth in Section 4(a). The Underwriters
shall not be under any obligation to purchase any Additional Shares prior to the exercise of the Over-allotment Option. The Over-allotment
Option may be exercised in whole or in part, and may be exercised more than once, during the 45-day period. The Over-allotment Option
may be exercised by the giving of oral notice to the Company from the Underwriters, which shall be confirmed in writing via overnight
mail or facsimile or other electronic transmission, setting forth the number of Additional Shares to be purchased and the date and time
for delivery of and payment for the Additional Shares (the “Option Closing Date”), which shall not be later than five
(5) full business days after the date of the notice or such other time as shall be agreed upon by the Company and the Underwriters, at
the offices of the counsel to the Underwriters, or at such other place (including remotely by facsimile or other electronic transmission)
as shall be agreed upon by the Company and the Representative. If such delivery and payment for the Additional Shares does not occur on
the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise of the Over-allotment Option with respect
to all or any portion of the Additional Shares, subject to the terms and conditions set forth herein, (i) the Company shall become obligated
to sell to the Underwriters the number of Additional Shares specified in such notice and (ii) the Underwriters shall purchase that portion
of the total number of Additional Shares.

(g) Payment for
the Additional Shares shall be made on the Option Closing Date by wire transfer in federal (same day) funds, upon delivery to the Underwriters
of certificates (in form and substance satisfactory to the Underwriters) representing the Additional Shares (or through the facilities
of DTC) for the account of the Underwriters. The Additional Shares shall be registered in such name or names and in such authorized denominations
as the Underwriters may request in writing at least two (2) full business days prior to the Option Closing Date. The Company shall not
be obligated to sell or deliver the Additional Shares except upon tender of payment by the Underwriters for applicable Additional Shares.

5. Covenants.

(a) The Company covenants and
agrees with the Underwriters as follows:

(i) The Company shall
prepare the Final Prospectus in a form approved by the Representative and file such Final Prospectus pursuant to Rule 424(b) under the
Securities Act not later than the Commission’s close of business on the second business day following the execution and delivery
of this Agreement, or, if applicable, such earlier time as may be required by the Rules and Regulations.

(ii) During the period
beginning on the date hereof and ending on the later of the Closing Date or such date as determined by the Representative the Final Prospectus
is no longer required by law to be delivered in connection with sales by an underwriter or dealer (the “Prospectus Delivery Period”),
prior to amending or supplementing the Registration Statement, including any Rule 462 Registration Statement, the Time of Sale Disclosure
Package or the Final Prospectus, the Company shall furnish to the Representative for review and comment a copy of each such proposed amendment
or supplement, and the Company shall not file any such proposed amendment or supplement to which the Representative reasonably objects.

(iii) From the date
of this Agreement until the end of the Prospectus Delivery Period, the Company shall promptly advise the Representative in writing (A)
of the receipt of any comments of, or requests for additional or supplemental information from, the Commission, (B) of the time and date
of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to the Time of Sale Disclosure
Package, the Final Prospectus or any Issuer Free Writing Prospectus, (C) of the time and date that any post-effective amendment to the
Registration Statement becomes effective and (D) of the issuance by the Commission of any stop order suspending the effectiveness of the
Registration Statement or of any order preventing or suspending its use or the use of the Time of Sale Disclosure Package, the Final Prospectus
or any Issuer Free Writing Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Common Stock
from any securities exchange upon which it is listed for trading or included or designated for quotation, or of the threatening or initiation
of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time during the Prospectus Delivery
Period, the Company will use its reasonable efforts to obtain the lifting of such order at the earliest possible moment. Additionally,
the Company agrees that it shall comply with the provisions of Rules 424(b), 430A or 430C
as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule
424(b) or Rule 433 were received in a timely manner by the Commission (without reliance on Rule 424(b)(8) or 164(b) of the Securities
Act).

(iv) (A) During the
Prospectus Delivery Period, the Company will comply with all requirements imposed upon it by the Securities Act, as now and hereafter
amended, and by the Rules and Regulations, as from time to time in force, and by the Exchange Act, as now and hereafter amended, so far
as necessary to permit the continuance of sales of or dealings in the Shares as contemplated by the provisions hereof, the Time of Sale
Disclosure Package, the Registration Statement and the Final Prospectus. If during the Prospectus Delivery Period any event occurs the
result of which would cause the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time
of Sale Disclosure Package ) to include an untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in light of the circumstances then existing, not misleading, or if during such period it is necessary or appropriate
in the opinion of the Company or its counsel or the Representative or counsel to the Underwriters to amend the Registration Statement
or supplement the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure
Package ) to comply with the Securities Act, the Company will promptly notify the Representative, allow the Representative the opportunity
to provide reasonable comments on such amendment, prospectus supplement or document, and will amend the Registration Statement or supplement
the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package)
or file such document (at the expense of the Company) so as to correct such statement or omission or effect such compliance.